Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1094 Articles

Jon C. Ogg | Oct 11, 2019 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto,…

Chris Lange | Oct 9, 2019 at 12:25 PM EDT

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to…

Chris Lange | Oct 2, 2019 at 10:50 AM EDT

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with…

Paul Ausick | Oct 1, 2019 at 12:00 PM EDT

Unusual Settlement Deal Proposed for Opioid Lawsuits

Five drugmakers are considering a proposal that would have them contribute to a trust established as part of the bankruptcy…

Lee Jackson | Sep 30, 2019 at 7:30 AM EDT

5 Dow Jones Industrial Average 2019 Laggards Could Be Big Q4 Winners

The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid…

Jon C. Ogg | Sep 13, 2019 at 7:11 AM EDT

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

As, when and if ESG themes continue to gain in popularity, imagine what could happen to some of the top-ranked…

Jon C. Ogg | Aug 27, 2019 at 11:25 AM EDT

Opioid Verdict: A Possible Victory for Johnson & Johnson and Loss for Everyone Else?

Johnson & Johnson is trading higher on the news, but some smaller public companies tied into the opioid crisis are…

Jon C. Ogg | Aug 12, 2019 at 12:10 PM EDT

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current…

Jon C. Ogg | Jul 18, 2019 at 7:20 AM EDT

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

Johnson & Johnson shares took a hit after earnings, but it was more than just the earnings and guidance to…

Jon C. Ogg | Jul 17, 2019 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, Cheniere, CSX, Johnson & Johnson, Motorola, Slack, Tilray, VMware and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Canopy Growth, Cheniere, CSX, Johnson & Johnson, Motorola,…

Jon C. Ogg | Jul 16, 2019 at 3:29 PM EDT

Why Johnson & Johnson Shareholders May Have to Ignore Earnings Looking Ahead

Johnson & Johnson shares traded lower despite beating earnings. It turns out that there are some issues outside of earnings…

Chris Lange | Jul 16, 2019 at 10:20 AM EDT

Johnson & Johnson Slides By With Q2 Earnings

Johnson & Johnson retreated though it reported better than expected second-quarter before the markets opened on Tuesday.

Chris Lange | Jul 15, 2019 at 12:55 PM EDT

What to Watch When Johnson & Johnson Reports Tomorrow

Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday.

Chris Lange | Jul 14, 2019 at 10:20 AM EDT

Microsoft, Netflix, eBay, Johnson & Johnson and More Major Earnings Coming This Week

24/7 Wall St. has put together a preview of Johnson & Johnson, Microsoft, Netflix and the other most prominent of…

Jon C. Ogg | Jul 9, 2019 at 8:35 AM EDT

Why ESG Investing May Become Problematic With Overlaps and Redundancy

24/7 Wall St. screened the top ESG ETFs to see how they differ or are similar. It turns out that…

1 … 20 21 22 23 24 … 73

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Unusual Settlement Deal Proposed for Opioid Lawsuits

5 Dow Jones Industrial Average 2019 Laggards Could Be Big Q4 Winners

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

Opioid Verdict: A Possible Victory for Johnson & Johnson and Loss for Everyone Else?

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, Cheniere, CSX, Johnson & Johnson, Motorola, Slack, Tilray, VMware and More

Why Johnson & Johnson Shareholders May Have to Ignore Earnings Looking Ahead

Johnson & Johnson Slides By With Q2 Earnings

What to Watch When Johnson & Johnson Reports Tomorrow

Microsoft, Netflix, eBay, Johnson & Johnson and More Major Earnings Coming This Week

Why ESG Investing May Become Problematic With Overlaps and Redundancy

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Unusual Settlement Deal Proposed for Opioid Lawsuits

5 Dow Jones Industrial Average 2019 Laggards Could Be Big Q4 Winners

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

Opioid Verdict: A Possible Victory for Johnson & Johnson and Loss for Everyone Else?

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, Cheniere, CSX, Johnson & Johnson, Motorola, Slack, Tilray, VMware and More

Why Johnson & Johnson Shareholders May Have to Ignore Earnings Looking Ahead

Johnson & Johnson Slides By With Q2 Earnings

What to Watch When Johnson & Johnson Reports Tomorrow

Microsoft, Netflix, eBay, Johnson & Johnson and More Major Earnings Coming This Week

Why ESG Investing May Become Problematic With Overlaps and Redundancy

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%